How do you pay?

How to pay the least

Ask for the cash price

Etcamah

We didn’t find one.

  1. Ask your pharmacy for Etcamah’s cash price, and one or two other pharmacies too.
  2. Etcamah’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Specialty and Primary products, your annual adjusted gross income must be at or below 300% of the Federal Poverty Level Or call 1-800-292-6363.

See if you qualify 

Compare every option

Question
Brand nameEtcamah
Authorized genericcamizestrant
Regular genericcamizestrant
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Etcamah?
The original
–
–

Brand nameThe maker’s card

ETCAMAH Co-pay Savings Program (AstraZeneca Access 360)

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on myaccess360.com 

Or call 1-844-275-2360.

In the maker’s words

“Eligible patients may pay as little as $0 per month for ETCAMAH.”

From the maker’s offer on myaccess360.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Etcamah itself, from the same company, sold without the brand name, and usually for less. For now Etcamah is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

ETCAMAH is an estrogen receptor antagonist indicated:

  • in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA authorized test.
  • This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Etcamah (AstraZeneca Pharmaceuticals LP), September 4, 2026. Full label on DailyMed 

Good to know